Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.34 |
| ▸ | HTR1B | P28222 | 7/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19113714 | 1.00 | HTR1D (0.34) | HTR1DHTR1BKMT2ACYP2A6CYP2A13 | |
| SCHEMBL13922060 | 0.84 | KMT2A (0.34) | HTR1DHTR1BKMT2ACYP2A6CYP2A13 | |
| SCHEMBL10016896 | 0.68 | OPRM1 (0.41) | HTR1DHTR1BKMT2ACYP2A6 | |
| SCHEMBL14025938 | 0.67 | — | — | |
| SCHEMBL11836208 | 0.67 | ADRA1A (0.54) | CYP2A6CYP2A13ALDH1A1TSHR | |
| SCHEMBL22628861 | 0.67 | ADRA1A (0.54) | CYP2A6CYP2A13ALDH1A1TSHR | |
| SCHEMBL15984747 | 0.67 | CYP2A6 (0.37) | KMT2ACYP2A6CYP2A13ALDH1A1TSHR | |
| SCHEMBL12424334 | 0.67 | DRD2 (0.43) | KMT2ATSHR | |
| SCHEMBL15147099 | 0.66 | PLAU (0.56) | TSHR | |
| SCHEMBL598142 | 0.66 | PLAU (0.56) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | HTR1D 357/4885HTR1B 1281/4885KMT2A 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.